Stockscreener 앱 받기
0.6424
8.53%
0.0505
시간 외 거래:
.67
0.0276
+4.30%
전일 마감가:
$0.5919
열려 있는:
$0.5813
하루 거래량:
4.71M
Relative Volume:
0.69
시가총액:
$142.63M
수익:
$2.04M
순이익/손실:
$-43.21M
주가수익비율:
-3.1079
EPS:
-0.2067
순현금흐름:
$-105.93M
1주 성능:
-17.47%
1개월 성능:
-42.64%
6개월 성능:
-64.11%
1년 성능:
-56.00%
1일 변동 폭
$0.575
$0.6575
1주일 범위
$0.5469
$0.7699
52주 변동 폭
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.6424 | 131.41M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Why BTIG cut its target on Humacyte (HUMA) but kept a bullish view on the bigger opportunity - MSN
HC Wainwright Issues Positive Forecast for Humacyte Earnings - MarketBeat
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte, Inc. (HUMA) Shares Decline Despite Overall Market Rise: The Reason Explained - Bitget
HUMA: Benchmark Downgrades Humacyte with Lowered Price Target | - GuruFocus
Benchmark Reaffirms "Speculative Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Benchmark Downgrades Humacyte to Speculative Buy From Buy, Adjusts Price Target to $1 From $11 - moomoo.com
Earnings Miss: Can Humacyte Inc sustain its profitabilityPortfolio Growth Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Macro: Does Humacyte Inc Equity Warrant have declining or rising EPS2026 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
Piper Sandler Cuts Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Piper Sandler cuts Humacyte stock price target on weak sales - Investing.com UK
Piper Sandler cuts Humacyte stock price target on weak sales By Investing.com - Investing.com Canada
TD Cowen Has Lowered Expectations for Humacyte (NASDAQ:HUMA) Stock Price - MarketBeat
TD Cowen lowers Humacyte stock price target to $1 on launch concerns - investing.com
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Cuts Target Price to $1 - moomoo.com
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $1 - moomoo.com
Humacyte, Inc. (HUMA) reports Q4 loss, misses revenue estimates - MSN
Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity - Yahoo Finance
Smart Money: Does Humacyte Inc Equity Warrant have declining or rising EPSPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
5 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Humacyte earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Humacyte misses revenue target despite in-line earnings By Investing.com - ca.investing.com
Humacyte 10-K: Revenue $2.04M, EPS $(0.26) - TradingView
Humacyte (NASDAQ: HUMA) details Symvess FDA approval, launch and ATEV pipeline in 10-K - Stock Titan
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia - MSN
Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital - MarketBeat
Humacyte shares see BTIG price target cut to $3 on lower sales outlook - Investing.com UK
Humacyte shares see BTIG price target cut to $3 on lower sales outlook By Investing.com - Investing.com India
Humacyte (NASDAQ:HUMA) Issues Earnings Results - MarketBeat
BTIG Research Lowers Humacyte (NASDAQ:HUMA) Price Target to $3.00 - MarketBeat
Humacyte Q4 2025 earnings preview - MSN
Humacyte Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Humacyte Q4 2025 revenue misses forecast By Investing.com - Investing.com Australia
Earnings call transcript: Humacyte Q4 2025 revenue misses forecast - investing.com
HUMA: Symvess adoption grows with strong clinical data, improved pricing, and expanding global reach - TradingView
Humacyte Inc reports results for the quarter ended December 31Earnings Summary - tradingview.com
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte earnings matched, revenue fell short of estimates - Investing.com
Humacyte misses revenue target despite in-line earnings - investing.com
Humacyte posts bigger-than-expected Q4 loss - TradingView
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - marketscreener.com
BRIEF-Humacyte Q4 Basic EPS USD -0.13 - TradingView
HUMA Should I Buy - Intellectia AI
Dip Buying: Can Humacyte Inc deliver consistent EPS growth2026 Big Picture & Growth Focused Investment Plans - baoquankhu1.vn
Humacyte, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Humacyte, Inc. (HUMA) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development - Bitget
Humacyte appoints Rick McElheny as SVP of business development - investing.com
Humacyte appoints Rick McElheny as SVP of business development By Investing.com - Investing.com Canada
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.47%
자본화:
|
볼륨(24시간):